Success Metrics

Active Trials
5(100%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

recruiting360%
active_not_recruiting240%

Recent Activity

5 active trials
Showing 5 of 5
recruitingphase_3

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07690371
active_not_recruitingphase_2

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT06136741
recruitingphase_3

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07711418
active_not_recruitingphase_2

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

NCT06340360
recruitingphase_2

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

NCT07142252

Clinical Trials (5)

Showing 5 of 5 trials
NCT07690371Phase 3

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
NCT06136741Phase 2

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Active Not Recruiting
NCT07711418Phase 3

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
NCT06340360Phase 2

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Active Not Recruiting
NCT07142252Phase 2

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5